This Biotech Stock Has Soared 175%. Here's Why One Fund Still Sold $3 Million Worth
2026-05-09 12:13:57 ET
On May 8, 2026, JW Asset Management reported selling 83,600 shares of Liquidia Corporation (NASDAQ:LQDA) , an estimated $3.10 million trade based on quarterly average pricing.
According to an SEC filing dated May 8, 2026, JW Asset Management reduced its holdings in Liquidia by 83,600 shares. The estimated transaction value, calculated using the average closing price for the first quarter of 2026, was $3.10 million. After the trade, the fund reported holding 16,176 shares worth $610,482 at quarter-end. The net position value decreased by $2.83 million over the period.
Liquidia Corporation is a biotechnology company focused on developing and commercializing therapies for pulmonary arterial hypertension and other rare diseases. The company leverages proprietary drug delivery technology to address significant unmet needs in the U.S. healthcare market.
NASDAQ: LQDA
LQDA Trading
21.73% G/L:
$66.17 Last:
2,617,784 Volume:
$55.14 Open:
